This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
McDonald, C. M. et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 399, 1049–1058 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lempriere, S. Treatment with cardiosphere-derived cells could slow progress of Duchenne muscular dystrophy. Nat Rev Neurol 18, 251 (2022). https://doi.org/10.1038/s41582-022-00657-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00657-2